In episode 5, Michael and Josh dive into the complex world of hormone receptor-positive breast cancer. While early-stage breast cancer boasts fantastic cure rates many other cancers can only dream of, this evolving space must contend with multiple players, including aromatase inhibitors, tamoxifen and now abemaciclib (CDK 4/6 inhibitor). How best to approach adjuvant endocrine therapy is difficult, but Michael and Josh are on the case!
Links to papers discussed in this episode (subscription may be required):
SOFT/TEXT: Prudence et al. (2018): https://www.nejm.org/doi/full/10.1056/NEJMoa1803164
MonarchE: Johnston et al. (2020): https://pubmed.ncbi.nlm.nih.gov/32954927/
For more episodes, resources and blog posts, visit inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}